Empagliflozin improves serum uric acid and early cardiometabolic outcomes in asymptomatic hyperuricemia among patients with type 2 diabetes: A 6-month observational study
Abstract
Asymptomatic hyperuricemia is common among patients with type 2 diabetes and has been associated with increased cardiovascular risk. However, evidence regarding the effects of empagliflozin on serum uric acid (SUA) and cardiovascular outcomes in this population remains limited. This study aimed to evaluate the impact of empagliflozin on SUA levels and early cardiometabolic outcomes in patients with type 2 diabetes and asymptomatic hyperuricemia. This 6-month observational study was conducted at a tertiary hospital in Vietnam. A total of 247 patients with type 2 diabetes were included in the cross-sectional analysis. Among them, 63 patients with asymptomatic hyperuricemia who did not meet indications for urate-lowering therapy were followed prospectively for 6 months and received either empagliflozin (10-25 mg/d) or background therapy without empagliflozin. Changes in SUA, HbA1c, fasting plasma glucose, and major adverse cardiovascular events (MACE) were assessed. Among the 247 participants, 73 (29.6%) had asymptomatic hyperuricemia and showed a significantly higher incidence of MACE than those without hyperuricemia (34.2% vs 8.6%; adjusted odds ratio 5.77, 95% CI: 2.49-13.39). SUA demonstrated good predictive performance for MACE (AUC 0.741), cardiovascular mortality (AUC 0.804), and myocardial infarction (AUC 0.745). After 6 months, SUA decreased more significantly in the empagliflozin group than in the control group (-101.66 ± 76.44 vs -45.90 ± 86.36 µmol/L; P = .009).…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 247 participants or records.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.